Advantage Investment Management LLC purchased a new stake in shares of Amgen, Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,015 shares of the medical research company’s stock, valued at approximately $879,000.
A number of other large investors have also added to or reduced their stakes in the company. New York Life Trust Co. increased its position in shares of Amgen by 54.8% in the third quarter. New York Life Trust Co. now owns 624 shares of the medical research company’s stock valued at $104,000 after buying an additional 221 shares during the period. Penserra Capital Management LLC increased its position in shares of Amgen by 100.0% in the third quarter. Penserra Capital Management LLC now owns 684 shares of the medical research company’s stock valued at $114,000 after buying an additional 342 shares during the period. Oakworth Capital Inc. increased its position in shares of Amgen by 1.4% in the third quarter. Oakworth Capital Inc. now owns 711 shares of the medical research company’s stock valued at $119,000 after buying an additional 10 shares during the period. Focused Wealth Management Inc increased its position in shares of Amgen by 248.0% in the fourth quarter. Focused Wealth Management Inc now owns 870 shares of the medical research company’s stock valued at $127,000 after buying an additional 620 shares during the period. Finally, Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen during the fourth quarter valued at about $157,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.
Amgen, Inc. (NASDAQ:AMGN) traded down 0.96% during midday trading on Friday, reaching $160.48. 2,039,119 shares of the company’s stock traded hands. Amgen, Inc. has a 52-week low of $133.64 and a 52-week high of $184.21. The firm has a market cap of $118.19 billion, a PE ratio of 15.67 and a beta of 1.15. The firm’s 50-day moving average is $169.01 and its 200 day moving average is $158.67.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, February 2nd. The medical research company reported $2.89 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.79 by $0.10. The company had revenue of $5.97 billion for the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a net margin of 33.59% and a return on equity of 29.42%. The firm’s revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the firm posted $2.61 EPS. Equities research analysts expect that Amgen, Inc. will post $12.33 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 8th. Investors of record on Wednesday, May 17th will be paid a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.84%. The ex-dividend date of this dividend is Monday, May 15th. Amgen’s dividend payout ratio is presently 44.92%.
ILLEGAL ACTIVITY WARNING: “Advantage Investment Management LLC Takes Position in Amgen, Inc. (AMGN)” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://sportsperspectives.com/2017/04/21/advantage-investment-management-llc-buys-shares-of-6015-amgen-inc-amgn-updated.html.
Several research analysts have recently issued reports on AMGN shares. Royal Bank of Canada set a $190.00 price target on shares of Amgen and gave the stock a “buy” rating in a report on Wednesday, January 4th. Zacks Investment Research downgraded shares of Amgen from a “hold” rating to a “sell” rating in a report on Tuesday, January 3rd. Jefferies Group LLC downgraded shares of Amgen from a “buy” rating to a “hold” rating and lowered their price target for the stock from $194.00 to $180.00 in a report on Wednesday, April 5th. Bank of America Corp upgraded Amgen from a “neutral” rating to a “buy” rating and increased their price objective for the company from $156.68 to $192.00 in a report on Wednesday, February 1st. Finally, Vetr upgraded Amgen from a “sell” rating to a “hold” rating and set a $174.10 price objective for the company in a report on Monday, March 20th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $186.94.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.